Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity
Shipra Gandhi(Roswell Park Comprehensive Cancer Center), Marc S. Ernstoff(Roswell Park Comprehensive Cancer Center)
Cited by 137
Related Papers
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
|Journal for ImmunoTherapy of Cancer|2017|2k
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
|Journal for ImmunoTherapy of Cancer|2021|804